showed that combination therapy with CIK cells plus a PD-1 blocking antibody might increase CD3+ CD16+ CD56+ T cells, reversing the resistance to anti-PD-1 antibody treatment, and enhancing the clinical response in patients with NSCLC (42). Here, PDCD1 is linked to non-small cell lung carcinoma.